Paperpal Prime Logo

Frontiers in Pharmacology : Impact Factor & More

eISSN: 1663-9812pISSN: 1663-9812
JournalOpen Access

Key Metrics

CiteScore
6.6
Eigenfactor
0.05 - 0.1
Impact Factor
5 - 10
Scite Index
0.91 5-Year SI
SJR
Q1Pharmacology
SNIP
1.39
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Frontiers in Pharmacology

Frontiers in Pharmacology Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher FRONTIERS MEDIA SA
Language English
Frequency Continuous publication
Article Processing ChargesUSD 2950
Publication Time14
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2010
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 14
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY
OA statementVisit website
View less

Planning to publish in Frontiers in Pharmacology ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Frontiers in Pharmacology

Immune-related adverse reactions across multiple systems in a non-small cell lung cancer patient induced by immune checkpoint inhibitors: a case report and literature review
  • 23 Oct 2026
  • Frontiers in Pharmacology
ABT score based clinical model predicts prognosis in unresectable hepatocellular carcinoma treated with TACE combined with bevacizumab and sintilimab therapy
  • 23 Oct 2026
  • Frontiers in Pharmacology
Cotinus coggygria Scop. extract-loaded polycaprolactone/hyaluronic acid nanofibers as candidate wound dressings: in vitro characterization, cytocompatibility and antibacterial evaluation
  • 23 Oct 2026
  • Frontiers in Pharmacology
Safety profiles of current and emerging neoadjuvant immune-modulatory and combination strategies in borderline resectable stage III non-small cell lung cancer: a narrative review
  • 23 Oct 2026
  • Frontiers in Pharmacology
The impact of GLP-1 receptor agonists on chemotherapeutic efficacy: insights from GWAS and experiments
  • 23 Oct 2026
  • Frontiers in Pharmacology
Engineered hyalurosomal gel co-delivering citicoline sodium and nifedipine for potential glaucoma management: formulation and pharmacodynamic evaluation
  • 23 Oct 2026
  • Frontiers in Pharmacology
Immune-related adverse reactions across multiple systems in a non-small cell lung cancer patient induced by immune checkpoint inhibitors: a case report and literature review
  • 23 Oct 2026
  • Frontiers in Pharmacology
ABT score based clinical model predicts prognosis in unresectable hepatocellular carcinoma treated with TACE combined with bevacizumab and sintilimab therapy
  • 23 Oct 2026
  • Frontiers in Pharmacology
Cotinus coggygria Scop. extract-loaded polycaprolactone/hyaluronic acid nanofibers as candidate wound dressings: in vitro characterization, cytocompatibility and antibacterial evaluation
  • 23 Oct 2026
  • Frontiers in Pharmacology
Safety profiles of current and emerging neoadjuvant immune-modulatory and combination strategies in borderline resectable stage III non-small cell lung cancer: a narrative review
  • 23 Oct 2026
  • Frontiers in Pharmacology
The impact of GLP-1 receptor agonists on chemotherapeutic efficacy: insights from GWAS and experiments
  • 23 Oct 2026
  • Frontiers in Pharmacology
Engineered hyalurosomal gel co-delivering citicoline sodium and nifedipine for potential glaucoma management: formulation and pharmacodynamic evaluation
  • 23 Oct 2026
  • Frontiers in Pharmacology

FAQs on Frontiers in Pharmacology